Cirrhotic cardiomyopathy

Orphanet Journal of Rare Diseases

Volumn 2, Issue 1, 2007, Pages

  Baik, Soon Koo ^a   Fouad, Tamer R ^b   Lee, Samuel S ^b  

^a Yonsei University Wonju   (South Korea)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; CARDIOMYOPATHY; DIFFERENTIAL DIAGNOSIS; HEART DISEASE; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW;

ANIMALS; CARDIOMYOPATHIES; DIAGNOSIS, DIFFERENTIAL; HEART DISEASES; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PROGNOSIS;

EID: 34247889877     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-2-15     Document Type: Review

References (80)

1. Kowalski HJ, Abelmann WH: The cardiac output at rest in Laennec's cirrhosis, J Clin Invest 1953, 32:1025-1033.
2. Abelmann WH, Kowalski HJ, McNeely WF: The hemodynamic response to exercise in patients with Laennec's cirrhosis. J Clin Invest 1955, 34:690-695.
3. Ma Z, Lee SS: Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepotology 1996, 24:451-459.
4. Liu H, Lee SS: Cardiopulmonary dysfunction in cirrhosis. J Gastroenterol Hepatol 1999, 14:600-608.
5. Myers RP, Lee SS: Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000, 6(4 Suppl 1):S44-S52.
6. Lee SS: Cardiac abnormalities in liver cirrhosis. West J Med 1989, 151:530-535.
7. Liu H, Song D, Lee SS: Cirrhotic cardiomyopathy. Gostroenterol Clin Biol 2002, 26:842-847.
8. Regan TJ, Levinson GE, Oldewurtel HA, Frank MJ, Weisse AB, Moschos CB: Ventricular function in noncardiacs with alcoholic fatty liver: role of ethanol in the production of cardiomyopathy. J Clin Invest 1969, 48:397-407.
9. Gould L, Zahir M, Shariff M, DiLieto M: Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J Clin Invest 1969, 48:860-868.
10. Limas CJ, Guiha NH, Lekagul O, Cohn JN: Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 1974, 49:754-760.
11. Caramelo C, Fernandez-Munoz D, Santos JC, Blanchart A, Rodriguez-Puyol D, Lopez-Novoa JM, Hernando L: Effect of volume expan sion on hemodynamics, capillary permeability and renal function in conscious, cirrhotic rats. Hepatology 1986, 6: 129-134.
12. Ingles AC, Hernandez I, Garcia-Estan J, Quesada T, Carbonell LF: Limited cardiac preload reserve in conscious cirrhotic rats. Am J Physiol 1991, 260:H1912-917.
13. Lee SS, Marty J, Mantz J, Samain E, Braillon A, Lebrec D: Desensitization of myocardial β-adrenergic receptors in cirrhotic rats. Hepatology 1990, 12:481-485.
14. Kelbaek H, Eriksen J, Brynjolf I, Raboel A, Lund JO, Munck O, Bonnevie O, Godtfredsen J: Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cordiol 1984, 54:852-855.
15. Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IA, Hayes PC: Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol 1995, 22:326-332.
16. Finucci G, Desideri A, Sacerdoti D, Bolognesi M, Merkel C, Angeli P, Gatta A: Left ventricular diastolic function in liver cirrhosis. Scand J Gostroenterol 1996, 31:279-284.
17. Pozzi M, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S, Bolla GB, Roffi L, Failla M, Grassi G, Giannattasio C, Mancia G: Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997, 26:1 131-1137.
18. Wong F, Liu P, Lilly L, Bomzon A, Blendis L: Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond) 1999, 97:259-267.
19. Wong F, Girgrah N, GrabaJ, Allidina Y, Liu P, Blendis L: The cardiac response to exercise in cirrhosis. Gut 2001, 49:268-75.
20. Blendis L, Wong F: Is there a cirrhotic cardiomyopathy? Am J Gostroenterol 2000, 95:3026-3028.
21. Moller S, Henriksen JH: Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002, 87:9-15.
22. Gaskari SA, Honar H, Lee SS: Therapy insight: cirrhotic cardiomyopathy. Not Clin Pract Gostroenterol Hepatol 2006, 3:329-337.
23. Ramond MJ, Comoy E, Lebrec D: Alternations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity, Br J Clin Pharmacol 1986, 21:191-196.
24. Kempler P, Szalay F, Varadi A, Keresztes K, Kadar E, Tanczos E, Petrik J: Prolongation of the QTc-interval reflects the severity of autonomic neuropathy in primary biliary cirrhosis and in other non-alcoholic liver diseases. Z Gostroenterol 1993, 31(Suppl2):96-98.
25. Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, Schepis F, Mandini M, Simoni P, Contin M, Raimondo G: Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998, 27:28-34.
26. Trevisani F, Merli M, Savelli F, Valeriane V, Zambruni A, Riggio O, Caraceni P, Domenicali M, Bernardi M: QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt, J Hepatol 2003, 38:461-467.
27. Bal JS, Thuluvath PJ: Prolongation of QTc interval: relationship with etiology and severity of liver disease, mortality and liver transplantation. Liver Int 2003, 23:243-248.
28. Zambruni A, Trevisani F, Caraceni P, Bernardi M: Cardiac electro-physiological abnormalities in patients with cirrhosis. J Hepatol 2006, 44:994-1002.
29. Stein LB, Dabezies MA, Silverman M, Brozena SC: Fatal torsade de pointes occurring in a patient receiving intravenous vasopressin and nitroglycerin. J Clin Gostroenterol 1992, 15:171-174.
30. Faigel DO, Metz DC, Kochman ML: Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalance. Am J Gostroenterol 1995, 90:822-824.
31. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Moller S: Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002, 36:513-520.
32. Ward CA, Ma Z, Lee SS, Giles WR: Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol 1997, 273:G537-544.
33. Ward CA, Liu H, Lee SS: Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. Gostroenterology 2001, 121:1209-1218.
34. Jaue DN, Ma Z, Lee SS: Cardiac muscarinic receptor function in rats with cirrhotic cardiomyopathy. Hepatology 1997, 25:1361-1365.
35. Therapondos G, Flapan AD, Plevris JN, Hayes PC: Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl 2004, 10:1441-1453.
36. Torregrosa M, Aguade S, Dos L, Segura R, Gonzalez A, Evangelista A, Castell J, Margarit C, Esteban R, Guardia J, Genesca J: Cardiac alterations in cirrhosis: reversibility after liver transplantation. Journal of Hepatology 2005, 42:68-74.
37. Park SC, Beerman LB, Gärtner JC, Zitelli BJ, Malatack JJ, Fricker FJ, Fischer DR, Mathews RA, Neches WH, Zuberbuhler JR: Echocardiographic findings before and after liver transplantation. Am J Cordiol 1985, 55:1373-1378.
38. Glauser FL: Systemic hemodynamic and cardiac function changes in patients undergoing orthotopic liver transplantation. Chest 1990, 98:1210-1215.
39. Nasraway SA, Klein RD, Spanier TB, Rohrer RJ, Freeman RB, Rand WM, Benotti PN: Hemodynamic correlates of outcome in patients undergoing orthotopic liver transplantation. Evidence for early postoperative myocardial depression. Chest 1995, 107:218-224.
40. Sampathkumar P, Lerman A, Kim BY, Narr BJ, Poterucha JJ, Torsher LC, Plevak DJ: Post-liver transplantation myocardial dysfunction. Liver Transpl Surg 1998, 4:399-403.
41. Donovan CL, Marcovitz PA, Punch JD, Bach DS, Brown KA, Lucey MR, Armstrong WF: Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 1996, 61:1180-1188.
42. Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rossle M: Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999, 44:743-748.
43. Lotterer E, Wengert A, Fleig WE: Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology 1999, 29:632-639.
44. Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, De CS, Riggio O: Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gostroenterol 2002, 97:142-148.
45. Braverman AC, Steiner MA, Picus D, White H: High-output congestive heart failure following transjugular intrahepatic portal-systemic shunting. Chest 1995, 107:1467-1469.
46. Gines P, UrizJ, Calahorra B, Garcia-Tsao G, Kamath PS, Del Arbol LR, Planas R, Bosch J, Arroyo V, Rodes J: Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gostroenterology 2002, 123:1839-1847.
47. Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, Meregaglia D, Nicolini A: Diastolic dysfunction is associated with poor survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Gut in press, (online access Nov 2006); doi: 10.1136/gut.2006.102467.
48. Lee SS, Liu H: Cardiovascular determinants of survival in cirrhosis. Gut in press.
49. Ruiz-del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, Albillos A, Jimenez W, Arroyo V: Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003, 38:1210-1218.
50. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, Milicua JM, Jimenez W, Arroyo V: Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005, 42:439-447.
51. Lee SS: Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy? Hepatology 2003, 38:1089-1091.
52. Le Grimellec C, Friedlander G, el Yandouzi EH, Zlatkine P, Giocondi MC: Membrane fluidity and transport properties in epithelia. Kidney Int 1992, 42:825-836.
53. Ma Z, Meddings JB, Lee SS: Membrane physical properties determine cardiac beta-adrenergic receptor function in cirrhotic rats. Am J Physiol 1994, 267:687-93.
54. Ma Z, Miyamoto A, Lee SS: Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gostroenterology 1996, 110:1 191-1198.
55. Van Obbergh L, Vallieres Y, Biaise G: Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide related. J Hepatol 1996, 24:747-752.
56. Liu H, Ma Z, Lee SS: Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gostroenterology 2000, 118:937-944.
57. Garcia-Estan J, Ortiz MC, Lee SS: Nitric oxide and renal and cardiac dysfunction in cirrhosis. Gin Sci (Land) 2002, 102:213-222.
58. Liu H, Song D, Lee SS: Role of heme oxygenase-carbon monoxide pathway in pathogenesis of cirrhotic cardiomyopathy in the rat. Am J Physiol 2001, 280:G68-74.
59. Cohen RA, Weisbrod RM, Gericke M, Yaghoubi M, Bierl C, Bolotina VM: Mechanism of nitric oxide-induced vasodilatation: refilling of intracellular stores by sarcoplasmic reticulum Ca2+ ATPase and inhibition of store-operated Ca2+ influx. Grc Res 1999, 84:210-219.
60. Pacher P, Batkai S, Kunos G: Cirrhotic cardiomyopathy: an endocannabinoid connection? British Journal of Pharmacology 2005, 146:313-314.
61. Ford WR, Honan SA, White R, Hiley CR: Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts, Br Pharmacol 2002, 135:1191-1198.
62. Bonz A, Laser M, Kullmer S, Kniesch S, Babin-Ebell J, Popp V, Ertl G, Wagner JA: Cannabinoids acting on CBI receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 2003, 41:657-664.
63. Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, Lee SS: Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats, Br J Pharmacol 2005, 146:315-323.
64. Yamamoto K, Burnett JC Jr. Jougasaki M, Nishimura RA, Bailey KR, Saito Y, Nakao K, Redfield MM: Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996, 28:988-994.
65. Motwani JG, McAlpine H, Kennedy N, Struthers AD: Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 1993, 341:1109-1110.
66. Gines P, Jimenez W, Arroyo V, Navasa M, Lopez C, Tito L, Serra A, Bosch J, Sanz G, Rivera F: Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology 1988, 8:636-642.
67. La Villa G, Romanelli RG, Casini Raggi V, Tosti-Guerra C, De Feo ML, Marra F, Laffi G, Gentilini P: Plasma levels of brain natriuretic peptide in patients with cirrhosis. Hepatology 1992, 16:156-161.
68. Wong F, Siu S, Liu P, Blendis L: Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis. Clin Sci 2001, 101:621-628.
69. Henriksen JH, Gøtze JP, Fuglsang S, Christensen E, Bendtsen F, Moller S: Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003, 52:1511-1517.
70. Pateron D, Beyne P, Laperche T, Logeard D, Lefilliatre P, Sogni P, Moreau R, Langlet P, Elman A, Bernuau J, Valla D, Erlinger S, Lebrec D: Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 1999, 29:640-643.
71. Bernardi M, Rubboli A, Trevisani F, Cancellieri C, Ligabue A, Baraldini M. Gasbarrini G: Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. Hepatology 1991, 12:207-216.
72. Plotkin JS, Johnson LB, Rustgi V, Kuo PC: Coronary artery disease and liver transplantation: the state of the art. Liver Transpl 2000, 6(4 Suppl 1):S53-56.
73. Ma Z, Lee SS: Management of cirrhotic cardiomyopathy. In Medical Management of Liver Disease Edited by: Krawitt EL. New York, NY, USA: Marcel Dekker; 1999:583-589.
74. Mikulic E, Munoz C, Puntoni LE, Lebrec D: Hemodynamic effects of dobutamine in patients with alcoholic cirrhosis. Clin Pharmacol Ther 1983, 34:56-59.
75. Orii R, Sugawara Y, Hayashida M, Yamada Y, Chang K, Takayama T, Makuuchi M, Hanaoka K: Effects of amrinone on ischaemiareperfusion injury in cirrhotic patients undergoing hepatectomy: a comparative study with prostaglandin EI. Br J Anaesth 2000, 85:389-395.
76. Henriksen JH, Bendtsen F, Hansen EF, Moller S: Acute non-selective beta-adrenergic blockade reduces prolonged frequencyadjusted Q-T interval (QTc) in patients with cirrhosis. J Hepatol 2004, 40:239-246.
77. Pozzi M, Grassi G, Ratti L, Favini G, Dell'Oro R, Redaelli E, Calchera I, Boari G, Mancia G: Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis. Am J Gostroenterol 2005, 100:1110-1116.
78. Starzl TE, Demetris AJ, Van Thiel D: Medical progress: Liver transplantation. N Engl J Med 1989, 321:1092-1099.
79. Gayowski T, Marino IR, Singh N, Doyle H, Wagener M, Fung JJ, Starzl TE: Orthotopic liver transplantation in high-risk patients: Risk factors associated with mortality and infectious morbidity. Transplantation 1998, 65:499-504.
80. Liu H, Lee SS: What happens to cirrhotic cardiomyopathy after liver transplantation? Hepatology 2005, 42:1203-1205.